{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T16:02:54Z","timestamp":1760889774042,"version":"3.37.3"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Polish National Science Center","award":["UMO-2013\/11\/B\/NZ7\/01638"],"award-info":[{"award-number":["UMO-2013\/11\/B\/NZ7\/01638"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["POPW.01.03.00-06-009\/11-00"],"award-info":[{"award-number":["POPW.01.03.00-06-009\/11-00"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejmech.2019.01.031","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T14:00:03Z","timestamp":1548252003000},"page":"144-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands"],"prefix":"10.1016","volume":"166","author":[{"given":"Grzegorz","family":"\u015alifirski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Kr\u00f3l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Kleps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szymon","family":"Ulenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"B\u0105czek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Siwek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Stachowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadeta","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Bojarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna E.","family":"Kozio\u0142","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Tur\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciszek","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.01.031_bib1","first-page":"1","article-title":"Depression, a global public health concern","author":"World Health Organization","year":"2012","journal-title":"WHO Dep. Ment. Heal. Subst. Abus."},{"key":"10.1016\/j.ejmech.2019.01.031_bib2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","article-title":"Risk for recurrence in depression","volume":"27","author":"Burcusa","year":"2007","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.ejmech.2019.01.031_bib3","series-title":"The Global Burden of Disease: 2004 update","first-page":"146","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.ejmech.2019.01.031_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jad.2017.02.029","article-title":"Restoring function in major depressive disorder: A systematic review","volume":"215","author":"Sheehan","year":"2017","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.ejmech.2019.01.031_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/138945006775515446","article-title":"Pindolol Augmentation of Antidepressant Response","volume":"7","author":"Artigas","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2019.01.031_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.12688\/f1000research.9736.1","article-title":"Serotonin receptors in depression: from A to B","volume":"6","author":"Nautiyal","year":"2017","journal-title":"F1000Research."},{"key":"10.1016\/j.ejmech.2019.01.031_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02246053","article-title":"Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists","volume":"119","author":"Detke","year":"1995","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.ejmech.2019.01.031_bib8","first-page":"1606","volume":"18","author":"Samuels","year":"2016","journal-title":"Critical for the Antidepressant Response"},{"key":"10.1016\/j.ejmech.2019.01.031_bib9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0165-6147(94)90315-8","article-title":"Current advances and trends in the treatment of depression","volume":"15","author":"Blier","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2019.01.031_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0893-133X(96)80055-8","article-title":"The 5-HT1A receptor: Signaling, desensitization, and gene transcription","volume":"14","author":"Albert","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2019.01.031_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2019.01.031_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nurt.2008.10.039","article-title":"Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs","volume":"6","author":"Millan","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2019.01.031_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroscience.2017.05.021","article-title":"Chronic Fluoxetine Rescues Changes In Plasma Membrane Density of 5\u2013HT1A Autoreceptors and Serotonin Transporters in the Olfactory Bulbectomy Rodent Model of Depression","author":"Riad","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2019.01.031_bib14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/syn.890010511","article-title":"Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: Electrophysiological studies in the rat brain","volume":"1","author":"Blier","year":"1987","journal-title":"Synapse"},{"key":"10.1016\/j.ejmech.2019.01.031_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","article-title":"The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder","volume":"11","author":"Sahli","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.01.031_bib16","series-title":"Vortioxetine (brintellix): a new serotonergic antidepressant","first-page":"36","author":"D'Agostino","year":"2015"},{"key":"10.1016\/j.ejmech.2019.01.031_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: Preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","author":"Newman-Tancredi","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.ejmech.2019.01.031_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.01.031_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.euroneuro.2013.04.013","article-title":"Developments in the field of antidepressants, where do we go now?","volume":"25","author":"Artigas","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2019.01.031_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","article-title":"Serotonin receptors involved in antidepressant effects","volume":"137","author":"Artigas","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.01.031_bib21","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.ejmech.2008.09.021","article-title":"Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, Part 1","volume":"44","author":"Herold","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib22","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1016\/j.ejmech.2009.07.007","article-title":"Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity: Part 2","volume":"44","author":"Herold","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejmech.2010.10.026","article-title":"Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. part 3","volume":"46","author":"Herold","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejmech.2014.10.069","article-title":"Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 4","volume":"90","author":"Chodkowski","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2015.05.003","article-title":"Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. part 5","volume":"98","author":"Gomolka","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib26","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1016\/j.bmcl.2005.07.028","article-title":"Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists","volume":"15","author":"Cole","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.01.031_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1021\/jm049243i","article-title":"Discovery of 5-Arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H -indole Derivatives as Potent, Selective 5-HT6 Receptor Agonists and Antagonists","volume":"48","author":"Cole","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib28","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1016\/j.bmc.2009.08.006","article-title":"Indene-based frameworks targeting the 5-HT6 serotonin receptor: Ring constraint in indenylsulfonamides using cyclic amines and structurally abbreviated counterparts","volume":"17","author":"Alcalde","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib29","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1016\/j.bmcl.2005.06.067","article-title":"2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists","volume":"15","author":"Mattsson","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.01.031_bib30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ejmech.2013.03.006","article-title":"Structure\u2013activity relationship of 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole analogues as 5-HT6 receptor agonists","volume":"63","author":"Mattsson","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib31","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1021\/jo00103a052","article-title":"Use of 2,5-Dimethylpyrrole as an Amino-Protecting Group in an Efficient Synthesis of 5-Amino-3-[(N-methyl- pyrrolidin-2(R)-yl)methyl]indole","volume":"59","author":"Macor","year":"1994","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib32","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/jm300343m","article-title":"Mitigating heterocycle metabolism in drug discovery","volume":"55","author":"Jean","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib33","doi-asserted-by":"crossref","first-page":"10185","DOI":"10.1016\/0040-4020(96)00553-4","article-title":"3-(Tetrahydropyridinyl)indoles","volume":"52","author":"Gharagozloo","year":"1996","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2019.01.031_bib34","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0040-4020(01)00023-0","article-title":"Synthesis of new bridged tetrahydro-\u03b2-carbolines and spiro-fused quinuclidines","volume":"57","author":"Burm","year":"2001","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2019.01.031_bib35","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1021\/jm100007m","article-title":"Conformational Refinement of Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration of 3-Piperidin-3-ylindole Analogues of Dacinostat (LAQ824)","volume":"53","author":"Cho","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"year":"2017","series-title":"Mthfd2 inhibitors and uses thereof, WO 2004\/043949 A1","author":"Mainolfi","key":"10.1016\/j.ejmech.2019.01.031_bib36"},{"year":"2017","series-title":"version 2017.1.2","author":"ACD\/ChemSketch","key":"10.1016\/j.ejmech.2019.01.031_bib37"},{"key":"10.1016\/j.ejmech.2019.01.031_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2019.01.031_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0028-3908(85)90153-4","article-title":"The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(DI-n-propylamino)tetralin (8-OH-DPAT)","volume":"24","author":"Goodwin","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2019.01.031_bib40","series-title":"Serotonin Mol. Biol. Recept. Funct. Eff","first-page":"483","article-title":"8-OH-DPAT-Induced Hypothermia in Rodents. A Specific Model of 5-HTlA Autoreceptor Function?","author":"Martin","year":"1991"},{"key":"10.1016\/j.ejmech.2019.01.031_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0014-2999(95)00234-C","article-title":"A\u00a0pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635","volume":"281","author":"Forster","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.01.031_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A\u00a0short history of SHELX","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Crystallogr. A"},{"key":"10.1016\/j.ejmech.2019.01.031_bib43","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.01.031_bib44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ejmech.2018.01.002","article-title":"Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects","volume":"145","author":"Zajdel","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.031_bib45","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419300418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419300418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T20:40:42Z","timestamp":1565210442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419300418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":45,"alternative-id":["S0223523419300418"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.031","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}